Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors

<div>STROBE study flowchart and the number of individuals at each stage of the study. <sup>a</sup>Only those treated (class 1-2) and with a single record were included, to ensure data consistency. <sup>b</sup>The exact numbers are not reported because of a health and welfare data science center database center policy to avoid numbers ≤2 in single cells. <sup>c</sup>Without missing information in the TCR and death registry regarding survival status.</div>

Canadian Respiratory Journal

fig1

Figure 1

Figure 1: Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors 

Figure 1 | Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors 